CancerNetwork®’s Week in Review: March 15, 2021

Article

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, and urothelial cancer.

Each Monday, CancerNetwork® highlights the most important content from the previous week in oncology.

Among the top news from last week was an article covering a presentation on promising antibody-drug conjugates to treat patients with HER2-negative breast cancer with Kevin Kalinsky, MD, MS, from the 38th Annual Miami Breast Cancer Conference®.

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer

This review published in the Journal ONCOLOGY® highlights the existing data supporting the prognostic and predictive ability of the recurrence score in mode-positive breast cancer, current practice patterns related to recurrence score use in this population, and emerging applications.

Substantial existing data support the clinical utility of the recurrence score in patients with hormone receptor–positive/HER2-negative, node-positive breast cancer.

MRI-Guided Focused Ultrasound Ablation Shows Promising Early Outcomes in the Treatment of Prostate Cancer

Data published in Radiology found early positive results regarding the treatment of intermediate-risk prostate cancer with MRI-guided focused ultrasound ablation.

The early oncologic and functional outcomes were encouraging to the research team, suggesting the current options such as surgery and radiation therapy that eliminate the cancer but often leave patients with incontinence and sexual dysfunction can be improved upon.

Promising Antibody-Drug Conjugates Have the Potential to Change Treatment Landscape for HER2-Negative Breast Cancer

Kevin Kalinsky, MD, MS, discussed a number of antibody-drug conjugates, detailing the prevailing data and potential trials that may change the treatment paradigm for patients with breast cancer.

Specifically, Kalinsky touched on the data and prospective trials surrounding a number of ADCs, including sacituzumab govitecan (Trodelvy), ladiratuzumab vedotin, and trastuzumab deruxtecan (Enhertu), among others

Atezolizumab Indication in US Withdrawn for Previously Treated Metastatic Urothelial Cancer

As part of an industry-wide assessment of indications based on accelerated approval, Roche in consultation with the FDA has decided to withdraw the indication for atezolizumab (Tecentriq) in patients with urothelial carcinoma following platinum-based chemotherapy.

The decision was made in consultation with the FDA and is part of an industry-wide assessment of indications from accelerated approval that have not met requirements of confirmation.

Considering Lymphedema Is Key for Multimodality Therapy of Breast Cancer

Susan B. Kesmodel, MD, FACS, of the University of Miami, describes 3 methods by which breast surgical oncologists can strategize to reduce the incidence of lymphedema in patients undergoing surgery for breast tumors.

Kesmodel went on to say that the likelihood of lymphedema developing depends on interventions on the axilla, with the incidence being lowest in patients having sentinel lymph node biopsy alone and highest in those with axillary lymph node dissection.

For more updated from CancerNetwork®, make sure to follow us on Facebook, Twitter, and LinkedIn to stay up to date on the latest in oncology.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.